Delivery of sedative-hypnotics through an inhalation route
First Claim
1. A composition for delivery of zaleplon consisting of a condensation aerosol a. formed by volatilizing a thin layer of zaleplon on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of zaleplon and condensing the heated vapor of zaleplon to form condensation aerosol particles, b. wherein said condensation aerosol particles are characterized by less than 5% zaleplon degradation products, and c. the condensation aerosol has an MMAD of less than 3 microns.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to the delivery of sedative-hypnotics through an inhalation route. Specifically, it relates to aerosols containing sedative-hypnotics that are used in inhalation therapy. In a method aspect of the present invention, a sedative-hypnotic drug is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of a sedative-hypnotic, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% sedative-hypnotic drug degradation products. In a kit aspect of the present invention, a kit for delivering a sedative-hypnotic through an inhalation route is provided which comprises: a) a thin layer of a sedative-hypnotic drug and b) a device for dispensing said thin layer a sedative-hypnotic drug as a condensation aerosol.
-
Citations
18 Claims
-
1. A composition for delivery of zaleplon consisting of a condensation aerosol
a. formed by volatilizing a thin layer of zaleplon on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of zaleplon and condensing the heated vapor of zaleplon to form condensation aerosol particles, b. wherein said condensation aerosol particles are characterized by less than 5% zaleplon degradation products, and c. the condensation aerosol has an MMAD of less than 3 microns.
-
4. A composition for delivery of zolpidem consisting of a condensation aerosol
a. formed by volatilizing a thin layer of zolpidem on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of zolpidem and condensing the heated vapor of zolpidem to form condensation aerosol particles, b. wherein said condensation aerosol particles are characterized by less than 5% zolpidem degradation products, and c. the condensation aerosol has an MMAD of less than 3 microns.
-
7. A composition for delivery of zopiclone consisting of a condensation aerosol
a. formed by volatilizing a thin layer of zopiclone on a solid support, having the surface texture of a metal foil, to a temperature sufficient to produce a heated vapor of zopiclone and condensing the heated vapor of zopiclone to form condensation aerosol particles, b. wherein said condensation aerosol particles are characterized by less than 5% zopiclone degradation products, and c. the condensation aerosol has an MMAD of less than 3 microns.
-
10. A method of producing zaleplon in an aerosol form comprising:
-
a. heating a thin layer of zaleplon on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the zaleplon to form a heated vapor of the zaleplon, and b. during said heating, passing air through the heated vapor to produce aerosol particles of the zaleplon comprising less than 5% zaleplon degradation products, and an aerosol having an MMAD of less than 3 microns. - View Dependent Claims (11, 12)
-
-
13. A method of producing zolpidem in an aerosol form comprising:
-
a. heating a thin layer of zolpidem on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the zolpidem to form a heated vapor of the zolpidem, and b. during said heating, passing air through the heated vapor to produce aerosol particles of the zolpidem comprising less than 5% zolpidem degradation products, and an aerosol having an MMAD of less than 3 microns. - View Dependent Claims (14, 15)
-
-
16. A method of producing zopiclone in an aerosol form comprising:
-
a. heating a thin layer of zopiclone on a solid support, having the surface texture of a metal foil, to a temperature sufficient to volatilize the zopiclone to form a heated vapor of the zopiclone, and b. during said heating, passing air through the heated vapor to produce aerosol particles of the zopiclone comprising less than 5% zopiclone degradation products, and an aerosol having an MMAD of less than 3 microns. - View Dependent Claims (17, 18)
-
Specification